News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProGene Biomedical, Inc. Release: Ampersand Ventures Invests In IBT Reference Laboratory Funding To Expand IBT's Pharmaceutical Services Business



10/19/2005 5:12:20 PM

ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical reference laboratory specializing in clinical immunology and allergy testing, today announced that it has received $5 million in equity financing from Ampersand Ventures. The funding will be used to expand IBT's pharmaceutical services business supporting preclinical and clinical R&D at major pharmaceutical and biotechnology companies, as well as add to its menu of specialized diagnostic tests offered to hospitals, physician practices and major clinical reference laboratories.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES